Cannabinoid hyperemesis and compulsive bathing: a case series and paradoxical pathophysiological explanation
…, A Medvecz, B Hagerty, L Krijger… - The Journal of the …, 2010 - Am Board Family Med
Cannabinoid hyperemesis is a syndrome characterized by severe nausea and hyperemesis
associated with chronic marijuana abuse and marked by compulsive bathing habits, which …
associated with chronic marijuana abuse and marked by compulsive bathing habits, which …
[CITATION][C] Analysis of defective alleles encoding the human vitamin D receptor and causing hypocalcemic rickets
LC Krijger - 1991
Sequence polymorphisms in the apolipoprotein (a) gene. Evidence for dissociation between apolipoprotein (a) size and plasma lipoprotein (a) levels.
JC Cohen, G Chiesa, HH Hobbs - The Journal of clinical …, 1993 - Am Soc Clin Investig
… We wish to acknowledge the excellent technical assistance of Lisa Krijger, Tommy Hyatt,
Kathy Schueler, and Carla Leffert. We thank Eric Boerwinkle and Allan Gaw for helpful …
Kathy Schueler, and Carla Leffert. We thank Eric Boerwinkle and Allan Gaw for helpful …
Fibroblast growth factor-23 and risks of cardiovascular and noncardiovascular diseases: a meta-analysis
…, R di Giuseppe, A Bouma-de Krijger… - Journal of the …, 2018 - journals.lww.com
Background Fibroblast growth factor-23 (FGF-23) has been hypothesized to play a role in
the increased risk of cardiovascular disease in patients with CKD. Methods We identified …
the increased risk of cardiovascular disease in patients with CKD. Methods We identified …
[PDF][PDF] Comprehensive molecular characterization of pheochromocytoma and paraganglioma
…, L Cope, D Crain, E Curley, RR de Krijger… - Cancer cell, 2017 - cell.com
We report a comprehensive molecular characterization of pheochromocytomas and
paragangliomas (PCCs/PGLs), a rare tumor type. Multi-platform integration revealed that PCCs/…
paragangliomas (PCCs/PGLs), a rare tumor type. Multi-platform integration revealed that PCCs/…
Dopamine receptor expression and function in corticotroph ectopic tumors
…, A Faggiano, L Bodei, RR de Krijger… - The Journal of …, 2007 - academic.oup.com
Background: Dopamine receptor (DR) expression and dopamine agonist (DA) effectiveness
have never been demonstrated in neuroendocrine tumors associated with ectopic ACTH …
have never been demonstrated in neuroendocrine tumors associated with ectopic ACTH …
[HTML][HTML] 68Ga-PSMA PET/CT in radioactive iodine-refractory differentiated thyroid cancer and first treatment results with 177Lu-PSMA-617
LH de Vries, L Lodewijk, AJAT Braat, GC Krijger… - EJNMMI research, 2020 - Springer
Background Differentiated thyroid carcinoma (DTC) is the most common type of thyroid
cancer. Treatment with surgery, radioactive iodine (RAI), and TSH suppression is effective in …
cancer. Treatment with surgery, radioactive iodine (RAI), and TSH suppression is effective in …
[HTML][HTML] Sentinel lymph node detection in thyroid carcinoma using [68Ga]Ga-tilmanocept PET/CT: a proof-of-concept study
…, R van Rooij, LAA Brosens, RR de Krijger… - European journal of …, 2024 - Springer
Purpose Sentinel lymph node (SLN) biopsy is rarely used for thyroid carcinoma staging. This
is due to challenges associated with conventional Tc-99m-labeled tracers, often producing …
is due to challenges associated with conventional Tc-99m-labeled tracers, often producing …
Ariel: Enabling planetary science across light-years
Ariel, the Atmospheric Remote-sensing Infrared Exoplanet Large-survey, was adopted as
the fourth medium-class mission in ESA's Cosmic Vision programme to be launched in 2029. …
the fourth medium-class mission in ESA's Cosmic Vision programme to be launched in 2029. …
[HTML][HTML] Anti-GD2 based immunotherapy prevents late events in high-risk neuroblastoma patients over 18 months at diagnosis
ML Tas, LW Dootjes, M Fiocco, RR de Krijger… - Cancers, 2021 - mdpi.com
Simple Summary High-risk neuroblastoma accounts for 4% of newly diagnosed pediatric
malignancies, but for 9–10% of pediatric cancer mortality. To reduce the number of (late) …
malignancies, but for 9–10% of pediatric cancer mortality. To reduce the number of (late) …